Preoperative ropivacaine injection is beneficial in pars plana vitrectomy

Article

Administering an injection of 5 mL of 0.75% ropivacaine before pars plana vitrectomy reduces postoperative discomfort in patients

Administering an injection of 5 mL of 0.75% ropivacaine before pars plana vitrectomy reduces postoperative discomfort in patients, reveals an investigation in the journal Retina.

The study, led by Dr Carl-Ludwig Schönfeld, Augenklinik Herzog Carl Theodor, Munich, Germany, included 60 patients each randomly assigned 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 1, 3, or 5 mL pre- or 5 mL postoperatively. There were also 30 control patients who didn’t receive any additional analgesic treatment, Both groups were compared 1, 3 and 24 hours postoperatively.

The control group experienced a higher rate of postoperative pain, compared to those in the ropivacine group. The 5 mL dosage of ropivacine was the most effective pain reliever, compared to the 1 mL or 3 mL injection. The injections provide a benefit in analgesic demand and postoperative discomfort.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.